TY - JOUR
T1 - Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon
AU - Kim, Ho Min
AU - Haraguchi, Naotsugu
AU - Ishii, Hideshi
AU - Ohkuma, Masahisa
AU - Okano, Miho
AU - Mimori, Koshi
AU - Eguchi, Hidetoshi
AU - Yamamoto, Hirofumi
AU - Nagano, Hiroaki
AU - Sekimoto, Mitsugu
AU - Doki, Yuichiro
AU - Mori, Masaki
N1 - Funding Information:
ACKNOWLEDGMENT This study was supported in part by a grant from Core Research for Evolutional Science and Technology (CREST), a Grant-in-Aid for scientific research on Priority Areas (20012039), Grants-in-Aid for scientific research S (21229015) and C (20590313) from the Ministry of Education, Culture, Sports, Science, and Technology, and a grant from the Tokyo Biochemical Research Foundation, Japan.
PY - 2012/7
Y1 - 2012/7
N2 - Background: Recently, it has been reported that a small population of cancer stem cells (CSCs) play a role in resistance to chemotherapy and radiation therapy. We reported that CD13+ liver CSCs survive in hypoxic lesions after chemotherapy, presumably through increased expression of CD13/Aminopeptidase N, which is a scavenger enzyme in the reactive oxygen species (ROS) metabolic pathway. On the other hand, the concept of epithelial-mesenchymal transition (EMT) was indicated by a recent study showing an increased plasticity linked to the cellular "stemness" of CSCs. Methods: To study the relationship between CSCs and EMT, we examined biological characteristics of liver cancer cell lines with EMT by exposing transforming growth factor-β (TGF-β). Results: We showed that a TGF-β-induced EMT-like phenomenon is associated with increased CD13 expression in liver cancer cells. This phenomenon prevents further increases in the ROS level as well as the induction of apoptosis, promoting the survival of CD13+ CSCs, whereas inhibition of CD13 stimulates apoptosis. Immunohistochemical analysis also indicated that after chemotherapy, CD13 was coexpressed with N-cadherin in surviving cancer cells within fibrous capsules. We have demonstrated that CD13 expression plays a role in supporting the survival of CSCs and that there is an EMT-associated reduction in ROS elevation. Conclusions: This novel and consistent linkage between functional CSC markers and the EMT phenomenon suggests a bona fide candidate for targeted therapy for EMT-mediated invasion and metastasis of liver cancer.
AB - Background: Recently, it has been reported that a small population of cancer stem cells (CSCs) play a role in resistance to chemotherapy and radiation therapy. We reported that CD13+ liver CSCs survive in hypoxic lesions after chemotherapy, presumably through increased expression of CD13/Aminopeptidase N, which is a scavenger enzyme in the reactive oxygen species (ROS) metabolic pathway. On the other hand, the concept of epithelial-mesenchymal transition (EMT) was indicated by a recent study showing an increased plasticity linked to the cellular "stemness" of CSCs. Methods: To study the relationship between CSCs and EMT, we examined biological characteristics of liver cancer cell lines with EMT by exposing transforming growth factor-β (TGF-β). Results: We showed that a TGF-β-induced EMT-like phenomenon is associated with increased CD13 expression in liver cancer cells. This phenomenon prevents further increases in the ROS level as well as the induction of apoptosis, promoting the survival of CD13+ CSCs, whereas inhibition of CD13 stimulates apoptosis. Immunohistochemical analysis also indicated that after chemotherapy, CD13 was coexpressed with N-cadherin in surviving cancer cells within fibrous capsules. We have demonstrated that CD13 expression plays a role in supporting the survival of CSCs and that there is an EMT-associated reduction in ROS elevation. Conclusions: This novel and consistent linkage between functional CSC markers and the EMT phenomenon suggests a bona fide candidate for targeted therapy for EMT-mediated invasion and metastasis of liver cancer.
UR - http://www.scopus.com/inward/record.url?scp=84864987692&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864987692&partnerID=8YFLogxK
U2 - 10.1245/s10434-011-2040-5
DO - 10.1245/s10434-011-2040-5
M3 - Article
C2 - 21879266
AN - SCOPUS:84864987692
VL - 19
SP - S539-S548
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - SUPPL. 3
ER -